Fate Therapeutics (FATE) Receiving Somewhat Favorable Media Coverage, Accern Reports

Media headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1409048476544 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Fate Therapeutics stock traded down $0.54 during mid-day trading on Thursday, hitting $9.97. 408,662 shares of the company’s stock traded hands, compared to its average volume of 749,592. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $14.45. The company has a market capitalization of $507.67, a price-to-earnings ratio of -9.77 and a beta of 1.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts anticipate that Fate Therapeutics will post -0.94 earnings per share for the current fiscal year.

Several research firms have recently commented on FATE. UBS downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 6th. HC Wainwright downgraded Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a report on Tuesday, March 6th. Wells Fargo reissued an “outperform” rating and issued a $19.00 price objective (up previously from $10.00) on shares of Fate Therapeutics in a report on Tuesday, March 6th. BMO Capital Markets raised their price target on Fate Therapeutics from $7.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $10.00 price target (down previously from $19.00) on shares of Fate Therapeutics in a report on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Fate Therapeutics currently has an average rating of “Buy” and an average price target of $15.00.

COPYRIGHT VIOLATION NOTICE: This story was posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/04/05/fate-therapeutics-fate-earns-daily-news-impact-score-of-0-16/2027249.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.